A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor

被引:35
|
作者
Tan, DCW
Kini, RM
Jois, SDS
Lim, DKF
Xin, LX
Ge, RW [1 ]
机构
[1] Natl Univ Singapore, Dept Sci Biol, Singapore 119260, Singapore
[2] Natl Univ Singapore, Dept Pharm, Singapore 119260, Singapore
关键词
vascular endothelial growth factor (vascular; permeability factor); Flt-1(VEGFR-1); angiogenesis; Miles' assay; chick chorioallantoic membrane;
D O I
10.1016/S0014-5793(01)02314-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vascular endothelial growth factor (VEGF) is an angiogenic stimulator which functions through two endothelial specific tyrosine kinase receptors, Flt-1 and Flk-1, In this work, we show that an 11-amino acid peptide derived from the second immunoglobulin-like domain of Flt-1 functions as an angiogenic inhibitor in chick chorioallantoic membrane and inhibited VEGF-induced vascular permeability in Miles' assay without binding to VEGF directly, Circular dichroism and nuclear magnetic resonance analyses indicate that this peptide forms a stable extended structure in solution, presumably beta -sheet structure and is most likely existing as a dimer, Our results suggest that this small peptide functions as an angiogenic inhibitor by inhibiting VEGF function through a non-VEGF binding mechanism, (C) 2001 Federation of European Biochemical Societies, Published by Elsevier Science B,V, All rights reserved.
引用
收藏
页码:150 / 156
页数:7
相关论文
共 50 条
  • [31] Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis
    Caine, GJ
    Lip, GY
    Blann, AD
    ANNALS OF MEDICINE, 2004, 36 (04) : 273 - 277
  • [32] A fusion fragment from Flt-1 and KDR, acted as VEGF decoy receptor and exhibited anti-tumor function
    Li, Zhuang-Lin
    Yao, Xue-Jing
    Liu, Wei-Feng
    Chen, Guan-Jun
    BIOTECHNOLOGY LETTERS, 2010, 32 (11) : 1609 - 1613
  • [33] Functional convergence of Akt protein with VEGFR-1 in human endothelial progenitor cells exposed to sera from patient with type 2 diabetes mellitus
    Hassanpour, Mehdi
    Rezabakhsh, Aysa
    Rahbarghazi, Reza
    Nourazarian, Alireza
    Nouri, Mohammad
    Avci, Cigir Biray
    Ghaderi, Shahrooz
    Alidadyani, Neda
    Bagca, Bakiye Goker
    Bagheri, Hesam Saghaei
    MICROVASCULAR RESEARCH, 2017, 114 : 101 - 113
  • [34] Synergistic Anti-Angiogenic Effects Using Peptide-Based Combinatorial Delivery of siRNAs Targeting VEGFA, VEGFR1, and Endoglin Genes
    Egorova, Anna A.
    Shtykalova, Sofia, V
    Maretina, Marianna A.
    Sokolov, Dmitry, I
    Selkov, Sergei A.
    Baranov, Vladislav S.
    Kiselev, Anton, V
    PHARMACEUTICS, 2019, 11 (06)
  • [35] The ratio of membrane-bound form Flt-1 mRNA to VEGF mRNA correlates with tumor angiogenesis and prognosis in non-small cell lung cancer
    Takenaka, Kazumasa
    Katakura, Hiromichi
    Chen, Fengshi
    Ogawa, Eiji
    Adachi, Masashi
    Wada, Hiromi
    Tanaka, Fumihiro
    CANCER LETTERS, 2007, 246 (1-2) : 34 - 40
  • [36] Autologous Stem Cell Transplantation: Leukapheresis Product has Anti-angiogenic Effects In Vivo Correlating with Neutrophil-derived VEGFR1
    Luethy, Anita
    Stenner, Frank
    Lohri, Corinne
    Muller, Christoph
    Samaras, Panagiotis
    Steiner, Rudolf
    Van den Broek, Maries
    Mischo, Axel
    Renner, Christoph
    Knuth, Alexander
    Ruegg, Curzio
    Wenger, Roland H.
    Zweifel, Martin
    ANTICANCER RESEARCH, 2011, 31 (10) : 3115 - 3124
  • [37] Cartilage Repair in a Rat Model of Osteoarthritis Through Intraarticular Transplantation of Muscle-Derived Stem Cells Expressing Bone Morphogenetic Protein 4 and Soluble Flt-1
    Matsumoto, Tomoyuki
    Cooper, Gregory M.
    Gharaibeh, Burhan
    Meszaros, Laura B.
    Li, Guangheng
    Usas, Arvydas
    Fu, Freddie H.
    Huard, Johnny
    ARTHRITIS AND RHEUMATISM, 2009, 60 (05): : 1390 - 1405
  • [38] Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy
    Sun, Qiaoling
    Zhou, Jinghong
    Zhang, Zheng
    Guo, Mingchuan
    Liang, Junqing
    Zhou, Feng
    Long, Jingwen
    Zhang, Wei
    Yin, Fang
    Cai, Huaqing
    Yang, Haibin
    Zhang, Weihan
    Gu, Yi
    Ni, Liang
    Sai, Yang
    Cui, Yumin
    Zhang, Meifang
    Hong, Minhua
    Sun, Junen
    Yang, Zheng
    Qing, Weiguo
    Su, Weiguo
    Ren, Yongxin
    CANCER BIOLOGY & THERAPY, 2014, 15 (12) : 1635 - 1645
  • [39] Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours
    Soria, Jean-Charles
    Baselga, Jose
    Hanna, Nasser
    Laurie, Scott A.
    Bahleda, Rastislav
    Felip, Enriqueta
    Calvo, Emiliano
    Armand, Jean-Pierre
    Shepherd, Frances A.
    Harbison, Christopher T.
    Berman, David
    Park, Jong-Soon
    Zhang, Steven
    Vakkalagadda, Blisse
    Kurland, John F.
    Pathak, Ashutosh K.
    Herbst, Roy S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (08) : 1815 - 1824
  • [40] Parallel solid-phase synthesis of a small library of linear and hydrocarbon-bridged analogues of VEGF81-91: Potential biological tools for studying the VEGF/VEGFR-1 interaction
    Isabel Garcia-Aranda, Maria
    Marrero, Patricia
    Gautier, Benoit
    Martin-Martinez, Mercedes
    Inguimbert, Nicolas
    Vidal, Michel
    Teresa Garcia-Lopez, Maria
    Angeles Jimenez, Maria
    Gonzalez-Muniz, Rosario
    Jesus Perez de Vega, Maria
    BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (06) : 1978 - 1986